- Home
- CDRE vs DRUG Comparison
CDRE vs DRUG Comparison
Compare CDRE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- DRUG
- Stock Information
- Founded
- CDRE 2012
- DRUG 2019
- Country
- CDRE United States
- DRUG United States
- Employees
- CDRE N/A
- DRUG N/A
- Industry
- CDRE Industrial Specialties
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CDRE Health Care
- DRUG Health Care
- Exchange
- CDRE Nasdaq
- DRUG Nasdaq
- Market Cap
- CDRE N/A
- DRUG 233.2M
- IPO Year
- CDRE 2021
- DRUG N/A
- Fundamental
- Price
- CDRE $36.48
- DRUG $32.06
- Analyst Decision
- CDRE Strong Buy
- DRUG Strong Buy
- Analyst Count
- CDRE 1
- DRUG 5
- Target Price
- CDRE $37.00
- DRUG $83.25
- AVG Volume (30 Days)
- CDRE 331.4K
- DRUG 25.6K
- Earning Date
- CDRE 05-06-2025
- DRUG 05-20-2025
- Dividend Yield
- CDRE 1.04%
- DRUG N/A
- EPS Growth
- CDRE N/A
- DRUG N/A
- EPS
- CDRE 0.95
- DRUG N/A
- Revenue
- CDRE $559,807,000.00
- DRUG N/A
- Revenue This Year
- CDRE $8.19
- DRUG N/A
- Revenue Next Year
- CDRE $8.18
- DRUG N/A
- P/E Ratio
- CDRE $38.53
- DRUG N/A
- Revenue Growth
- CDRE 10.06
- DRUG N/A
- 52 Week Low
- CDRE $27.07
- DRUG $0.93
- 52 Week High
- CDRE $40.28
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- CDRE 75.01
- DRUG 49.86
- Support Level
- CDRE $28.95
- DRUG $29.02
- Resistance Level
- CDRE $31.04
- DRUG $32.75
- Average True Range (ATR)
- CDRE 1.58
- DRUG 2.17
- MACD
- CDRE 0.74
- DRUG 0.01
- Stochastic Oscillator
- CDRE 91.62
- DRUG 46.41
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.